Abstract
RATIONALE: Specific immunotherapy with intact allergens is a well documented treatment for allergy. In Europe, several vaccine formulations are currently commercially available, the active ingredient being either intact allergens or chemically modified allergoids. The rationale behind allergoids is to decrease allergenicity while maintaining immunogenicity. However statistics from the German health authorities based on adverse events reporting over a 10 year period did not indicate increased safety of allergoids over intact allergens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
